Administration of acetylcholine and vasoactive intestinal polypeptide to atopic eczema patients.

Rukwied R, Heyer G

Experimental dermatology1 Feb 1999Cited by 34 (Europe PMC)

PMID10206720DOI10.1111/j.1600-0625.1999.tb00346.xPepBankPUB-10206720

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
After intracutaneous VIP injection, atopic eczema patients had smaller flare sizes than healthy controls.
In plain wordsIn people with atopic eczema, VIP injected into the skin caused a smaller flare than in healthy controls.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseFlare size after VIP injection, atopic eczema patients versus healthy controls
Study
n = 28
Comparator
Healthy controls
Outcome group
Skin reactions · Skin and wound
Studied dose
1.5 x 10(-5) M, 10 microl · intracutaneousAs given in this study (human).
Source sentences
Summary
Compared to healthy controls, after injection of ACh, VIP and the combination of VIP and ACh smaller flare sizes were recorded in AE patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Solutions of acetylcholine (ACh, 0.55 M) and vasoactive intestinal polypeptide (VIP, 1.5x 10(-5) M) were injected (10 microl) intracutaneously into the volar forearm of 14 healthy subjects and 14 atopic eczema (AE) patients.
Report a problemFND-1020672001
02HumanNon-randomized trialEfficacy outcome
After VIP injection, healthy controls reported significantly more pruritus than atopic eczema patients.
In plain wordsAfter a VIP skin injection, people with atopic eczema reported less itching than healthy controls.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreasePruritus after VIP injection, atopic eczema patients versus healthy controls
Study
n = 28
Comparator
Healthy controls
Outcome group
Skin reactions · Skin and wound
Studied dose
1.5 x 10(-5) M, 10 microl · intracutaneousAs given in this study (human).
Source sentences
Summary
After VIP was given, the control subjects reported pruritus, which was significantly augmented compared to AE patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Solutions of acetylcholine (ACh, 0.55 M) and vasoactive intestinal polypeptide (VIP, 1.5x 10(-5) M) were injected (10 microl) intracutaneously into the volar forearm of 14 healthy subjects and 14 atopic eczema (AE) patients.
Report a problemFND-1020672003
03HumanNon-randomized trialEfficacy outcome
In healthy controls, the final flare size was almost similar whether VIP and acetylcholine were injected together or separately.
In plain wordsIn healthy people, the skin flare was about the same whether VIP and acetylcholine were injected together or separately.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeFlare size with combined versus separate VIP and ACh in healthy controls
Study
n = 14
Comparator
VIP and ACh applied separately
Outcome group
Skin reactions · Skin and wound
Studied dose
1.5 x 10(-5) M, 10 microl · intracutaneousAs given in this study (human).
Source sentences
Summary
In control subjects the development and extension of the final flare size was almost similar, regardless whether ACh and VIP were applied in combination or separately.
1 context sentence(design, population, supporting numbers)
Summary · context
Solutions of acetylcholine (ACh, 0.55 M) and vasoactive intestinal polypeptide (VIP, 1.5x 10(-5) M) were injected (10 microl) intracutaneously into the volar forearm of 14 healthy subjects and 14 atopic eczema (AE) patients.
Report a problemFND-1020672005

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialEfficacy outcome
After combined VIP and acetylcholine injection, atopic eczema patients had smaller flare sizes than healthy controls.
In plain wordsIn people with atopic eczema, VIP and acetylcholine injected together into the skin caused a smaller flare than in healthy controls.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseFlare size after combined VIP and ACh injection, atopic eczema patients versus healthy controls
Study
n = 28
Comparator
Healthy controls
Outcome group
Skin reactions · Skin and wound
Source sentences
Summary
Compared to healthy controls, after injection of ACh, VIP and the combination of VIP and ACh smaller flare sizes were recorded in AE patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Solutions of acetylcholine (ACh, 0.55 M) and vasoactive intestinal polypeptide (VIP, 1.5x 10(-5) M) were injected (10 microl) intracutaneously into the volar forearm of 14 healthy subjects and 14 atopic eczema (AE) patients.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1020672002
05HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialEfficacy outcome
Itch after combined injection of VIP and acetylcholine was significantly elevated in atopic eczema patients.
In plain wordsIn people with atopic eczema, itch after VIP and acetylcholine injected together was significantly elevated.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseItch after combined VIP and ACh injection in atopic eczema patients
Study
n = 14
Outcome group
Skin reactions · Skin and wound
Source sentences
Summary
Itch sensation after the combined application of VIP and ACh was significantly elevated in AE patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Solutions of acetylcholine (ACh, 0.55 M) and vasoactive intestinal polypeptide (VIP, 1.5x 10(-5) M) were injected (10 microl) intracutaneously into the volar forearm of 14 healthy subjects and 14 atopic eczema (AE) patients.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1020672004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.